Vaxcyte PCVX
NASDAQ PCVX
$56.48 +0.43 (+0.77%)
At close: Oct 2, 2026 · 4:00 PM EDT

Vaxcyte (PCVX) Gains from Sales and Divestitures (2020 - 2022)

Updated

Vaxcyte (PCVX) recorded Gains from Sales and Divestitures of -$44,000 in FY2022, compared with -$97,000 in FY2021.

Analysis

Vaxcyte (PCVX) Gains from Sales and Divestitures (2020 - 2022) Analysis & Trends

Starting with FY2018, Vaxcyte's Gains from Sales and Divestitures history includes 5 years.

  • Annual Gains from Sales and Divestitures has ranged from -$97,000 in FY2021 to -$1,000 in FY2019 over the past five years.
  • Per Business Quant data, PCVX's Gains from Sales and Divestitures was -$97,000 in FY2021, -$34,000 in FY2020, -$1,000 in FY2019 and -$54,000 in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Vaxcyte 8.18 Bn 8.18 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 -44,000.00
Dec 31, 2021 -65,000.00
Sep 30, 2021 -32,000.00
Dec 31, 2020 -2,000.00
Sep 30, 2020 -16,000.00
API Access

Vaxcyte Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PCVX&period=max&api_key=YOUR_API_KEY